Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers

Gene Therapy

Volumn 7, Issue 10, 2000, Pages 896-902

  Modlich, U ^a   Pugh, C W ^b   Bicknell, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cytokine inducible enhancer; E selectin; Endothelial; Hypoxic enhancer; KDR; Promoter

Indexed keywords

CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOGLYCERATE KINASE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL SPECIFICITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENHANCER REGION; GENE INDUCTION; GENE TARGETING; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0034029495     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301177     Document Type: Article

References (30)

1. Jaggar RT et al. Endothelial cell-specific expression of tumor necrosis factor-a from the KDR or E-selectin promoters following retroviral delivery. Hum Gene Ther 1997; 8: 2239-2247.
2. Quinn TP et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7537.
3. Bevilacqua MP et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160-1165.
4. Brown LF et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
5. Kraling BM et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148: 1181-1191.
6. Fox SB et al The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol 1995; 177: 369-376.
7. Vaupel PW. Oxygenation of solid tumors. In: BA Teicher (ed.). Drug Resistance in Oncology. Marcel Decker: New York, 1993, pp 53-85.
8. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
9. Dachs GU et al. Targeting gene expression to hypoxic tumor cells. Nature Med 1997; 3: 515-520.
10. Maxwell PH et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109.
11. Maxwell PH et al. The tumour supressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolyses. Nature 1999; 399: 271-275.
12. Firth JD et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-6500.
13. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
14. Collins T et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J 1995; 9: 899-910.
15. Tian H, Mcknight SL, Russell DW. Endothelial pas domain protein 1 (Epas1), a transcription factor selectively expressed in endothelial cells. Gene Dev 1997; 11: 72-82.
16. Wiesener MS et al. Induction of endothelial Pas domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 alpha. Blood 1998; 92: 2260-2268.
17. Boyle EMJ et al. Transcriptional arrest of the human E-selectin gene. J Surg Res 1999; 82: 194-200.
18. Gerber H-P et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J Biol Chem 1997; 272: 23659-23667.
19. Yin LY et al. Genomic structure of the human KDR/flk-1 gene. Mamm Genome 1998; 9: 408-410.
20. Hata Y et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 1998; 273: 19294-19303.
21. Rappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999; 93: 4284-4292.
22. Patterson C et al. Nuclear protein interactions with the human KDR/Flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression. J Biol Chem 1997; 272: 8410-8416.
23. Giraudo E et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273: 22128-22135.
24. Patterson C et al. Down-regulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 1996; 98: 490-496.
25. Williams RL, Courtneidge SA, Wagner EF. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 1988; 52: 121-131.
26. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
27. Pepper MS et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 1994; 210: 298-305.
28. McCarthy SA, Bicknell R. Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction. J Biol Chem 1992; 267: 21617-21622.
29. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
30. Yu SF et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198.